LSKL, Inhibitor of Thrombospondin (TSP-1) TFA

Name: LSKL, Inhibitor of Thrombospondin (TSP-1) TFA
Brand: MedChemExpress
SKU: HY-P0299A
Rating: 5.0 (17 reviews)

Art. -Nr.: HY-P0299A Reinheit: 99.51%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

LSKL, Inhibitor of Thrombospondin (TSP-1) TFA is a latency-associated protein (LAP)-TGFβ derived tetrapeptide and a competitive TGF-β1 antagonist. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA inhibits the binding of TSP-1 to LAP and alleviates renal interstitial fibrosis and hepatic fibrosis. LSKL, Inhibitor of Thrombospondin (TSP-1) TFA suppresses subarachnoid fibrosis via inhibition of TSP-1-mediated TGF-β1 activity, prevents the development of chronic hydrocephalus and improves long-term neurocognitive defects following subarachnoid hemorrhage (SAH). LSKL, Inhibitor of Thrombospondin (TSP-1) TFA can readily crosse the blood-brain barrier.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Kundenspezifische Peptidsynthese

CAS. Nr. : 2828433-17-4

Größe	Verfügbarkeit	Menge
5 mg	Auf Lager	Estimated Time of Arrival: December 31
10 mg	Auf Lager	Estimated Time of Arrival: December 31
25 mg	Auf Lager	Estimated Time of Arrival: December 31
50 mg	Angebot einholen
100 mg	Angebot einholen

or Massenanfrage

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

This product is a controlled substance and not for sale in your territory.

Kundenbewertung

Based on 17 publication(s) in Google Scholar

Other Forms of LSKL, Inhibitor of Thrombospondin (TSP-1) TFA:

LSKL, Inhibitor of Thrombospondin (TSP-1) In-stock

17 Publications Citing Use of MCE LSKL, Inhibitor of Thrombospondin (TSP-1) TFA

RT-PCR

Histological Imaging/Staining

: LSKL, Inhibitor of Thrombospondin (TSP-1) TFA purchased from MedChemExpress. Usage Cited in: Sci Rep. 2025 Dec 23. [Abstract]; In HCT116 cells, after transfecting the over-expression plasmid for 48 h, LSKL (an inhibitor of the TGF-β1 pathway, 5 µmol/L) was added and the cells were incubated for an additional 24 h. In HT29 cells, after transfecting siRNA for 48 h, 10 ng/mL TGF-β1 (an activator of the TGF - β1 pathway) was added. After these treatments for both types of cells, the protein expression levels of Smad 2/3, p-Smad 2/3, and TGF-β1 were detected by Western blot assay.

: LSKL, Inhibitor of Thrombospondin (TSP-1) TFA purchased from MedChemExpress. Usage Cited in: PLoS One. 2024 Oct 7;19(10):e0311594. [Abstract]; A549 and BEAS-2B cells were treated with 5 ng/mL TGF-β1 and/or 20 μM LSKL for 48 h. The expression of proteins associated with TGF-β1 downstream signaling was assessed by western blotting.

: LSKL, Inhibitor of Thrombospondin (TSP-1) TFA purchased from MedChemExpress. Usage Cited in: Antioxidants (Basel). 2023 Nov 21;12(12):2024.; ICR mice were randomized into four groups: Control, LSKL, BLM + Control and BLM + LSKL. Protein levels of Grp78 and CHOP in lung tissues.

: LSKL, Inhibitor of Thrombospondin (TSP-1) TFA purchased from MedChemExpress. Usage Cited in: Antioxidants (Basel). 2023 Nov 21;12(12):2024.; ICR mice were randomized into four groups: Control, LSKL, BLM + Control and BLM + LSKL. Representative images of Masson’s trichrome staining of lung fibrosis.

: LSKL, Inhibitor of Thrombospondin (TSP-1) TFA purchased from MedChemExpress. Usage Cited in: Cancers. 2019 Dec 5;11(12):1946. [Abstract]; mRNA transcription level of occludin, ZO-1, VE-cadherin, in HUVECs treated with different amount of LSKL (0-100 μM).

Spezialitätsempfehlungen

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Alle TGF-β Receptor Isoform-spezifische Produkte anzeigen:

Alle Isoformen anzeigen

ALK1 ALK2 ALK3 ALK4 ALK5 ALK6 ALK7 TGFβR2 ACVR2A ACVR2B BMP

Biologische Aktivität
Reinheit & Dokumentation
Verweise
Kundenbewertung

Beschreibung

IC₅₀ & Target

TGF-β1^[1]

In Vitro

The KTFR sequence from ADAMTS1 is responsible for the interaction with the LSKL, Inhibitor of Thrombospondin (TSP-1) (LSKL peptide) from the latent form of TGF-β, leading to its activation. There is a stable binding mode between LSKL, Inhibitor of Thrombospondin (TSP-1) and ADAMTS1 KTFR sequence, characterized by 3 salt bridges and 2 hydrogen bonds^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

LSKL, Inhibitor of Thrombospondin (TSP-1) (1 mg/kg; intraperitoneal injection; male Sprague-Dawley rats) is protective against subarachnoid fibrosis, attenuates ventriculomegaly and effectively suppresses hydrocephalus. LSKL, Inhibitor of Thrombospondin (TSP-1) treatment inhibits TGF-β1 activity and subsequent Smad2/3 signaling^[1].
LSKL, Inhibitor of Thrombospondin (TSP-1) (30 mg/kg, i.p.) successfully inhibits transforming growth factor (TGF) β-Smad signal activation induced by partial hepatectomy. LSKL, Inhibitor of Thrombospondin (TSP-1) successfully attenuates TGF-β-Smad signal activation by antagonizing TSP-1, but not by reducing TSP-1 protein expression. LSKL, Inhibitor of Thrombospondin (TSP-1) accelerates hepatocyte proliferation after hepatectomy^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	103 male Sprague-Dawley rats (6 weeks of age; 160-180 g) with subarachnoid hemorrhage (SAH)^[1]
Dosage:	1 mg/kg
Administration:	Intraperitoneal injection
Result:	Was protective against subarachnoid fibrosis, attenuated ventriculomegaly and effectively suppressed hydrocephalus.

Molekulargewicht

458.60 (free base)

Formel

C₂₁H₄₂N₆O₅·xC₂HF₃O₂

CAS. Nr.

2828433-17-4

Appearance

Solid

Color

White to off-white

Sequence

Leu-Ser-Lys-Leu-NH2

Sequence Shortening

LSKL-NH2

Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 100 mg/mL

H₂O : 100 mg/mL (Need ultrasonic)

*"≥" means soluble, but saturation unknown.

Molaritätsrechner
Verdünnungsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL; Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL; Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 100 mg/mL; Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Reinheit & Dokumentation

Purity: 99.51%

Select Batch:

Data Sheet (277 KB) SDS (396 KB)

COA (250 KB) RP-HPLC (264 KB) MS (70 KB) Elemental Analysis Report (110 KB)

Handling Instructions (2659 KB)

Verweise

[1]. Liao F, et al. LSKL peptide alleviates subarachnoid fibrosis and hydrocephalus by inhibiting TSP1-mediated TGF-β1 signaling activity following subarachnoid hemorrhage in rats. Exp Ther Med. 2016 Oct;12(4):2537-2543. Epub 2016 Aug 31. [Content Brief]

[2]. Laurent MA, et al. In silico characterization of the interaction between LSKL peptide, a LAP-TGF-beta derived peptide, and ADAMTS1. Comput Biol Chem. 2016 Apr;61:155-61. [Content Brief]

[3]. Kuroki H, et al. Effect of LSKL peptide on thrombospondin 1-mediated transforming growth factor β signal activation and liver regeneration after hepatectomy in an experimental model. Br J Surg. 2015 Jun;102(7):813-25. [Content Brief]